Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NVS

3 Safe Stocks to Buy in an Unpredictable Market

The Fed’s intention to continue raising interest rates, disappointing economic data, and a weak earnings season could keep the stock market highly volatile. Hence, investing in quality stocks Microsoft (MSFT), Johnson (JNJ), and Novartis (NVS) could be safe. Continue reading.

StockNews.com

2 Pharma Stocks to Buy Now for Big Gains

The pharma industry is well-placed to benefit from the rise of chronic diseases and an aging population. Moreover, given the stable demand for medicines, the industry is relatively unaffected by macroeconomic uncertainty. Therefore, it could be wise for investors to buy fundamentally strong pharma stocks AstraZeneca (AZN) and Novartis (NVS).…

StockNews.com

The 3 Best Large-Cap Stocks to Buy Now and Hold Forever

Although the latest inflation and employment reports indicate a resilient economy, the Fed’s persistence to keep interest rates high has caused widespread concerns about an economic slowdown. With uncertainties surrounding the economy, we think it could be wise to buy and hold large-cap stocks Merck & Co. (MRK), Coca-Cola (KO),…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

1 Large-Cap Stock You Should Purchase This Week

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…

StockNews.com

3 Must Have Pharma Stocks in January 2023

Rising rates of chronic diseases, an aging population, and increasing healthcare spending should drive the pharma industry’s growth in the upcoming years. Moreover, pharma companies perform steadily regardless of economic conditions due to the inelastic demand for their products. Therefore, it could be wise to invest in fundamentally strong pharma…

StockNews.com

3 Pharmaceutical Stocks Under $100 to Buy This Week

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the economic uncertainties, investors could consider buying quality pharmaceutical stocks such as Pfizer (PFE), Novartis (NVS), and Bristol-Myers Squibb (BMY) this…

StockNews.com

2 Stable Stocks Every Investor Should Be Watching Now

The stock market is witnessing heightened volatility due to the multi-decade high inflation and the Fed’s rate hikes. Given the uncertainties ahead, fundamentally sound stocks Johnson & Johnson (JNJ) and Novartis (NVS), which seem relatively stable, might be ideal additions to your watchlist. Keep reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Novartis Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bullish stance on Novartis. Looking at options history for Novartis (NYSE:NVS) we detected 21 strange trades.

Benzinga

Rylan Clark first met new love interest Declan Doyle on The X Factor decade ago

The TV personality and Declan, who is the ex of Geordie Shore star Nathan Henry, have been spotted out and about looking cosy in recent weeks.

Daily Record

Rylan Clark first met his new love interest Declan Doyle on The X Factor 10 years ago

Rylan Clark and his rumoured new boyfriend Declan Doyle are said to be preparing to meet each others parents - 10 years on from first meeting thanks to The X Factor way back in 2012

Daily Mirror

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Benzinga

Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines

Novartis AG (NYSE:NVS) said that in early June, it restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey. It also resumed delivering doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to a temporary, voluntary suspension…

Benzinga

Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria

Novartis AG (NYSE:NVS) is pledging $250 million into R&D for new treatments of neglected tropical diseases (NTD) and malaria, with an aim to eliminate these diseases. "Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done," CEO Vas Narasimhan said. Novartis…

Benzinga

FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use

The FDA granted accelerated approval to Novartis AG's (NYSE:NVS) pairing of Tafinlar and Mekinist for any advanced solid tumors with the BRAF V600E mutation. The patient must have progressed following prior therapy and have no alternative treatment options. The combo is already approved for BRAF mutated non-small cell lung cancer, melanoma, and thyroid cancer.…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Durable Stocks to Strengthen Your Portfolio

Given the current market turmoil caused due to surging inflation and the Fed’s aggressive interest rate hikes to bring prices down, it could be wise to invest in stocks that do not fluctuate significantly in adverse market conditions. The solid stability of Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), Marubeni…

Birmingham Post

Work starts on National Veterinary Services' new Stoke-on-Trent warehouse

Winvic Construction has won the contract for the 253,000 sq ft unit at St Modwen Park Stoke Central on Festival Park

StockNews.com

5 No-Brainer Stocks to Buy if the Market Crashes

Novartis (NVS), Micron Technology (MU), Waste Management (WM), Oracle (ORCL), and Amgen (AMGN) have significant underlying strength of their businesses and therefore would be attractive buy if the stock market crashes.

StockNews.com

Worried About a Market Meltdown? Then Buy These 5 Stocks Now

The market’s near-term outlook remains uncertain on concerns over the persistent macroeconomic and geopolitical issues. But we think investors worried about a market meltdown can look to add quality stocks Coca-Cola FEMSA (KOF), CGI (GIB), Novartis (NVS), PLDT (PHI), and Fresenius Medical Care (FMS) to their portfolios because these names…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting

Novartis AG (NYSE:NVS) has announced updated median overall survival (OS) results for Kisqali (ribociclib) combined with fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. The analysis of patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly…

Benzinga

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

Benzinga

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized. Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2,…

Benzinga

Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook

Novartis AG (NYSE:NVS) has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44. Net income reached $2.2 billion, an increase of 8% or 15% at constant currency rates, mainly driven by higher operating income, partly offset by the loss of Roche Holding (OTC:RHHBY) income.…

Benzinga

Novartis Earnings Preview

Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report an earnings per share (EPS) of $1.44.

StockNews.com

5 Surging Mega-Cap Stocks to Add to Your Watchlist

The stock market has been experiencing high volatility due to various economic and geopolitical factors. But under these uncertain market conditions investors could add quality mega-cap stocks Novo Nordisk (NVO), Shell (SHEL), Eli Lilly (LLY), Novartis (NVS), and Costco (COST) to their watchlists. Mega-cap stocks are known to endure harsh…

StockNews.com

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

1 2 3 4

People

Rylan Clark

971 stories

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Microsoft Corporation

298 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.